ISIN | LU2041626032 |
---|---|
Valor Number | 49473298 |
Bloomberg Global ID | |
Fund Name | JSS Sustainable Equity - Future Health C CHF acc |
Fund Provider |
J. Safra Sarasin Investmentfonds AG
Basel, Switzerland Phone: +41 58 317 44 44 Web: www.jsafrasarasin.com |
Fund Provider | J. Safra Sarasin Investmentfonds AG |
Representative in Switzerland |
J. Safra Sarasin Investmentfonds AG Basel Phone: +41 58 317 44 00 |
Distributor(s) |
Bank J. Safra Sarasin AG Basel Phone: +41 58 317 44 00 |
Asset Class | Equities |
EFC Category | |
Distribution Policy | Accumulation |
Home Country | Luxembourg |
Issuing Condition | The fund management company and/or distributor charges an issuing commission (different commissions can be charged for the same fund depending on the sales channel) |
Redemption Condition | The fund does not charge any redemption commission and/or fees (units are redeemed at the NAV) |
Investment Strategy *** | The investment objective of the fund is to achieve long-term capital growth. The Reference Currency of the Sub-Fund is the US Dollar (USD). |
Peculiarities |
Current Price * | 101.34 CHF | 12.11.2024 |
---|---|---|
Previous Price * | 102.14 CHF | 08.11.2024 |
52 Week High * | 108.80 CHF | 16.07.2024 |
52 Week Low * | 87.97 CHF | 15.11.2023 |
NAV * | 101.34 CHF | 12.11.2024 |
Issue Price * | ||
Redemption Price * | ||
Closing Price * | ||
Indicative Minimum Price | ||
Fund Assets *** | 130,220,626 | |
Unit/Share Assets *** | 16,006,231 | |
Trading Information SIX |
YTD Performance | +10.81% |
29.12.2023 - 12.11.2024
29.12.2023 12.11.2024 |
---|---|---|
1 month | -1.62% |
15.10.2024 - 12.11.2024
15.10.2024 12.11.2024 |
3 months | -1.37% |
12.08.2024 - 12.11.2024
12.08.2024 12.11.2024 |
6 months | -1.68% |
13.05.2024 - 12.11.2024
13.05.2024 12.11.2024 |
1 year | +15.74% |
13.11.2023 - 12.11.2024
13.11.2023 12.11.2024 |
2 years | -6.03% |
14.11.2022 - 12.11.2024
14.11.2022 12.11.2024 |
3 years | -21.61% |
12.11.2021 - 12.11.2024
12.11.2021 12.11.2024 |
5 years | +1.34% |
21.11.2019 - 12.11.2024
21.11.2019 12.11.2024 |
Equity Participation Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Share of Total Fund Assets in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Real Estate Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI Date |
Eli Lilly and Co | 8.43% | |
---|---|---|
Danaher Corp | 5.66% | |
Boston Scientific Corp | 5.07% | |
Sanofi SA | 4.97% | |
Novo Nordisk AS Class B | 4.31% | |
Pfizer Inc | 3.77% | |
Zoetis Inc Class A | 3.67% | |
Biomarin Pharmaceutical Inc | 3.54% | |
Gilead Sciences Inc | 3.51% | |
Merck & Co Inc | 3.50% | |
Last data update | 30.09.2024 |
TER | 1.37% |
---|---|
TER date | 30.04.2024 |
Performance Fee *** | |
PTR | |
Max. Management Fee *** | 1.50% |
Ongoing Charges *** | 1.32% |
SRRI ***
|
|
SRRI date *** | 31.10.2024 |
Low Carbon Designation *** | |
---|---|
ESG Rating Overall *** | |
ESG Rating Corporate *** | |
ESG Rating Sovereign *** | |
% AuM H&S Controversies *** |
Avg Carbon Risk Score *** | |
---|---|
Avg Carbon Risk Cat Avg *** | |
% AuM Covered Carbon *** | |
Avg Fossil Fuel Exposure *** | |
Fossil Fuel Cat Avg *** |
Strategy Level 1 *** | |
---|---|
Strategy Level 2 *** | |
Strategy Level 3 *** | |
Exclusions Level 1 *** | |
Exclusions Level 2 *** |
GMOs |